Glenmark Pharmaceuticals has informed about the launch of Olanzapine for Injection, 10 mg/vial, Single?Dose Vial. Glenmark’s Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa® IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253]. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.